Vrancken, BramCuypers, LizePérez, Ana BelenChueca, NataliaAnton-Basantas, Joaquinde la Iglesia, AlbertoFuentes, JavierPineda, Juan AntonioTéllez, FranciscoBernal, EnriqueRincón, PilarVon Wichman, Miguel AngelFuentes, AnaVera, FranciscoRivero-Juárez, AntonioJiménez, MiguelVandamme, Anne-MiekeGarcía, Federico2023-01-252023-01-252019-10-01Vrancken B, Cuypers L, Pérez AB, Chueca N, Anton-Basantas J, de la Iglesia A, et al. Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. J Hepatol. 2019 Dec;71(6):1270-1272.0168-8278http://hdl.handle.net/10668/14584As of 2018, the majority of Western European countries – including Spain – have lifted restrictions to therapy based on disease severity in the context of HCV infections.1 Long overdue, most national elimination programmes now also include access to care for people who inject drugs (PWID),2 who are at the core of ongoing HCV transmission.3 Macías et al.4 have recently shown in this Journal that high viral cure rates can be achieved in this group, hereby providing evidence that targeting PWID in treatment programmes is worthwhile. However, the extent to which such national efforts can reduce the HCV burden not only depends on the uptake into care and treatment success rates, it is also determined by the relative importance of within-country transmission and virus importation from elsewhere.enEliminationEuropean UnionHCVNational strategyPWIDSpainAntiviral AgentsDrug UsersHepatitis CHepatitis C, ChronicHumansOpiate Substitution TreatmentSubstance Abuse, Intravenousresearch article31585736Restricted AccessEnfermedades rarasEvaluación de tecnologías sanitariasReembolso de medicamentosSistemas de recolección de datosDesarrollo basado en evidenciaAcuerdos de acceso gestionado10.1016/j.jhep.2019.08.0101600-0641https://www.journal-of-hepatology.eu/article/S0168-8278(19)30476-3/pdf